More recently, corin, a hybrid agent derived from the HDAC inhibitor entinostat and a tranylcypromine analog LSD inhibitor, has also been identified as a dual inhibitor of both HDAC1/2 and LSD1 with efficacy in several cancers including melanoma and breast cancer [64,65]. This evidence concerns the gene KDM1A and breast cancer.